



Atty Dkt No. 037003/0280647

Receipt #6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson, et al.

Group Art Unit: 1644

Application No. 09/911,703

Filed: July 25, 2001

RECEIVED
FEB 14 2002
TECH CENTER 1600/2900

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELLED
ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION
ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

* * * * *

REQUEST FOR CORRECTED FILING RECEIPT

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231
ATTN: Office of Initial Patent Examination Customer Service Center

Sir:

After careful review of the Filing Receipt, errors have been noted. It is requested that the errors be corrected so that the Filing Receipt reads as set forth below, and that Applicant be provided with a corrected Filing Receipt.

Under **TITLE**:

Please delete [radiolabeled] and insert -- radiolabelled --.


A redlined copy of the Filing Receipt is attached hereto. Applicant respectfully requests correction of the Filing Receipt and reissuance of the same.

A redlined copy of the Filing Receipt is attached hereto. Applicant respectfully requests correction of the Filing Receipt and reissuance of the same.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Dated: February 6, 2002

By 
Robin L. Teskin
Registration No. 35,030

Address all correspondence to:
1600 Tysons Boulevard
McLean, VA 22102
Tel: (703)905-2000
30260339v1



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/911,703	07/25/2001	1644	1516	P 0280647	21	47	7

CONFIRMATION NO. 4927

Intellectual Property Group
Pillsbury Winthrop LLP
1600 Tysons Boulevard
McLean, VA 22102

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

FILING RECEIPT



OC00000007311083

Date Mailed: 01/16/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Darrell R. Anderson, Escondido, CA;
Nabil hanna, Olivenhain, CA;
John E. Leonard, Encinitas, CA;
Roland A. Newman, San Diego, CA;
Mitchell E. Reff, San Diego, CA;
William H. Rastetter, Rancho Sante Fe, CA;

RECEIVED
FEB 14 2002
TECH CENTER 1600/2900

Assignment For Published Patent Application

IDEC Pharmaceuticals Corporation, San Diego, CA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 08/475,813 06/07/1995


Foreign Applications

If Required, Foreign Filing License Granted 01/15/2002

Projected Publication Date: To Be Determined - pending completion of Sequence Disclosures

Non-Publication Request: No

Early Publication Request: No



Title

RADIOLABELLED

Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov


Bib Data Sheet

CONFIRMATION NO. 4927

SERIAL NUMBER 09/911,703	FILING DATE 07/25/2001 RULE	CLASS 424	GROUP ART UNIT 1644	ATTORNEY DOCKET NO. P 0280647
------------------------------------	---	---------------------	-------------------------------	---

APPLICANTS

Darrell R. Anderson, Escondido, CA;
 Nabil hanna, Olivenhain, CA;
 John E. Leonard, Encinitas, CA;
 Roland A. Newman, San Diego, CA;
 Mitchell E. Reff, San Diego, CA;
 William H. Rastetter, Rancho Sante Fe, CA;

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

** CONTINUING DATA *****

THIS APPLICATION IS A CON OF 08/475,813 06/07/1995

** FOREIGN APPLICATIONS *****

IF REQUIRED, FOREIGN FILING LICENSE GRANTED

** 01/15/2002

Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY CA	SHEETS DRAWING 21	TOTAL CLAIMS 47	INDEPENDENT CLAIMS 7
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials		


ADDRESS

Intellectual Property Group
 Pillsbury Winthrop LLP
 1600 Tysons Boulevard
 McLean, VA 22102

TITLE

Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

FILING FEE RECEIVED 1516	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit



#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson, et al.

Group Art Unit: 1644

Application No. 09/911,703

Filed: July 25, 2001

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELLED ANTIBODIES
TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR
TREATMENT OF B CELL LYMPHOMA

* * * * *

REQUEST TO USE COMPUTER READABLE
SEQUENCE LISTING FORM FROM PARENT APPLICATION

Hon. Commissioner of Patents
2022 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence
Arlington, VA 22202
ATTN: CUSTOMER WINDOW


Sir:

Applicants advise that the computer readable form in the above-identified application is identical with that filed in U.S. Serial No. 09/475,813, filed June 7, 1995, which is a continuation of U.S. Serial No. 07/978,891, filed November 13, 1992.

Accordingly, in accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed in the parent application, Serial No. 09/475,813, as the computer readable form for the instant application. It is understood that the U.S. Patent & Trademark Office will make the necessary change in application and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing, as filed in the parent application, is to be incorporated into the present specification.

Respectfully submitted,
Pillsbury Winthrop LLP

Date: 2/6/02

By: 
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2200 Telephone
(703) 905-2500 Facsimile

RECEIVED
FEB 07 2002
TECH CENTER 1600/2900
RECEIVED
FEB 08 2002
TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



**ATTACHMENT TO "NOTICE TO COMPLY WITH
REQUIREMENTS...SEQUENCE DISCLOSURES"**

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be submitted using one of the following methods:

1. Electronically submitted through EFS-Bio
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>, EFS Submission User Manual - ePAVE)
2. Mailed to:
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202
3. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202
4. Hand Carried directly to the Customer Window at:
2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
Arlington, Virginia 22202

RECEIVED
FEB 08 2002
TECH CENTER 1000



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/911,703	07/25/2001	Darrell R. Anderson	P 0280647

CONFIRMATION NO. 4927

FORMALITIES LETTER



OC000000007311084

Intellectual Property Group
Pillsbury Winthrop LLP
1600 Tysons Boulevard
McLean, VA 22102

RECEIVED
FEB 07 2002
TECH CENTER 1600/2900
RECEIVED
FEB 08 2002
TECH CENTER 1600/2900

Date Mailed: 01/16/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.

A handwritten signature in black ink, consisting of stylized, overlapping loops and a long horizontal stroke at the end.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE